News

On World Alzheimer Day 2021, the NeurologyLive team has compiled interviews with experts in the field of Alzheimer disease care to offer up a summary of the latest in treatment and the remaining challenges.

Next steps for medical cannabis will need to include how cannabinoids affect the brain, according to the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel.

The director of The Women’s Alzheimer’s Movement Prevention Center at Cleveland Clinic discussed her recently awarded NIH grant and her work to understand why women are more likely to be impacted by Alzheimer disease.

Lisa Donahue PT, MPT, NCS, the director of Clinical Services at Evolution Devices, offered details about the EvoWalk platform, its potential in neurorehabilitation efforts, and its future clinical availability.

Both the 200-mg and 350-mg dose groups showed numerically advantageous differences over placebo in secondary end points such as average daily pain score and 30% reduction in ADP.

A study from the International Parkinson and Movement Disorder Society Virtual Congress suggest that despite protocol adherence, average costs are moderately high and vary significantly.

Deena Kuruvilla, MD, director, Westport Headache Institute, spoke to how the field and its related organizations might address the challenge of limited provider numbers, and what other efforts are required.

The neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel discussed future use of medical cannabis and concerns for psychiatric adverse effects.

Women with perimenstrual migraine attacks may also be at increased risk of medication overuse.

Here's what is coming soon to NeurologyLive.

The FIGHT-PD study is expected to complete and read out interim results before the end of 2021. It aims to assess the exercise program’s safety, tolerability, and efficacy in Parkinson disease.

The professor of neurology at Weill Cornell Medical School commented on the available treatments for Parkinson disease, as well as ongoing therapeutic development.

Patients previously randomized to omaveloxolone in the core study period continued to show no worsening on modified Friedrich Ataxia Rating Scale relative to their original baseline after nearly 2.5 years of treatment.

Patients who underwent deep brain stimulation procedures that were managed postoperatively in the home reported significantly fewer clinic visits with similar MDS-UPDRS scores to standard of care.

Investigators noted the psychiatric adverse effects of treatment with medical cannabis, requiring patient monitoring after initiation.

Despite not meeting the primary end point, those in the early-start group showed reduced change from baseline in MDS-UPDRS-III scores compared with the delayed-start group at both weeks 52 and 104.

Neurology News Network for the week ending September 18, 2021.

Data from the PRIME-NL study showed stressors resulting from the pandemic impacted depression, anxiety, and quality of life.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 17, 2021.

The president of the American Academy of Sleep Medicine emphasized the need to prioritize sleep for children and the organization’s efforts to improve sleep health.

Improvements in mean total amount of time and percentage of participants that were awake suggested limited effect with opicapone (Ogentys; Neurocrine Bio).

The director of the Movements Disorders Clinic at Houston Methodist Neurological Institute discussed data presented at the International Parkinson and Movement Disorders Society Virtual Congress 2021.

Patients with Parkinson disease in both the 24-hour and 16-hour ND0612 dosing regimen groups had ON-state UPDRS-motor scores and UPDRS-ADL scores improve over the 12-month period.

Deena Kuruvilla, MD, director, Westport Headache Institute, offered her insight into the trends in the clinical care of migraine and the effect that the pandemic has had on patients.

Participants in the pilot study saw improvements in short-term memory, attention, and executive functioning.

The director of the division of vascular neurology at the University of Utah discussed ongoing efforts from the AAN, as well as the potential to integrate advanced practice providers into neurology teams.

Data from MDS 2021 suggest that a 6-week brisk walking program can improve MDS-UPDRS nonmotor scores significantly compared to standard stretching interventions.

The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided a realistic perspective of when and how AI will be incorporated into the wider medical system.